From First-in-Human to Global Trials: How Emerging Biotechs and Biopharmas Can De-Risk Clinical Development

For emerging biotechs and biopharmas, the path from early-phase trials to global development is filled with operational and strategic risk. Increasing protocol complexity, fragmented vendor landscapes, and varying regulatory expectations add layers of uncertainty. In this talk, Adam Marsh will outline key inflection points where risk can be proactively mitigated, from study design through execution and scale-up. Attendees will leave with a clearer framework for reducing execution risk while enabling faster, more confident decision-making.

The 2026 Delivery Model: How Firms Cut 25% of Delivery Cost Without Cutting People

  • How firms redesigned delivery to increase margin, reduce risk and improve client outcomes.
  • Real examples of firms /How they reduced rework, chasing, manual entry, onboarding delays
  • How they used automation to remove friction, not replace people
  • The measurable impact on margin, WIP, write downs, and client satisfaction/ What “good” looks like